Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 103, Issue 6, Pages 1020-1028
Publisher
Wiley
Online
2018-02-27
DOI
10.1002/cpt.1056
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
- (2018) James J. Crawford et al. JOURNAL OF MEDICINAL CHEMISTRY
- First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
- (2018) John C. Byrd et al. Oncotarget
- Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
- (2016) Adam R. Johnson et al. ACS Chemical Biology
- Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton’s Tyrosine Kinase
- (2016) Samantha A. Chalmers et al. Scientific Reports
- Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss
- (2015) Akilan Krishnamurthy et al. ANNALS OF THE RHEUMATIC DISEASES
- Hypoxia-inducible factor-1α perpetuates synovial fibroblast interactions with T cells and B cells in rheumatoid arthritis
- (2015) Fanlei Hu et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Immunological events in chronic spontaneous urticaria
- (2015) Marta Ferrer Clinical and Translational Allergy
- Btk Regulates Macrophage Polarization in Response to Lipopolysaccharide
- (2014) Joan Ní Gabhann et al. PLoS One
- Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis
- (2013) A. L. Rankin et al. JOURNAL OF IMMUNOLOGY
- Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases
- (2013) L. Vargas et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis
- (2012) William P. Arend et al. Nature Reviews Rheumatology
- Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor
- (2011) Donald MacGlashan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy
- (2011) L. Liu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Mechanisms of tissue injury in lupus nephritis
- (2011) Tamara K Nowling et al. ARTHRITIS RESEARCH & THERAPY
- Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice
- (2010) K. Montag et al. INTERNAL MEDICINE JOURNAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now